Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OT-601-C
- Development stage
- Phase 2
- Lead developer
- Ocumension Biotech
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**OT-601-C** is an ophthalmic fixed-dose combination of the fluoroquinolone antibacterial moxifloxacin and the corticosteroid dexamethasone sodium phosphate, developed by Ocumension with Hangzhou Minsheng Pharmaceutical. It is formulated as eye drops for postoperative ocular inflammation, including inflammation following cataract surgery, in settings where bacterial infection is present or poses a risk. Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone activates the glucocorticoid receptor to suppress inflammatory signaling.
- Other names
- moxifloxacin-dexamethasone sodium phosphate
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on OT-601-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OT-601-C.